Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular senescence company Unity Biotechnology Inc. (NASDAQ:UBX), effective March 30. He succeeds Keith Leonard, who

Read the full 493 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE